Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%

Experimental Dermatology

Volumn 15, Issue 2, 2006, Pages 138-141

  Lakhanpaul, M ^a   Davies, T ^b   Allen, B Roger ^c   Schneider, D ^d  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Bridge Street Medical Practice ^*  (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atopic dermatitis; Blood concentrations; Elidel; Infants; Pimecrolimus

Indexed keywords

BETAMETHASONE VALERATE; PIMECROLIMUS; PREDNISOLONE; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREAM; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFANCY; INFANT; LONG TERM CARE; MALE; MULTIPLE DRUG DOSE; OPEN STUDY; SYSTEMIC THERAPY; TREATMENT DURATION; BLOOD; INTRADERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, ATOPIC; FEMALE; HUMANS; INFANT; MALE; TACROLIMUS;

EID: 33645119731     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2006.00398.x     Document Type: Article

References (11)

1. Allen B R, Lakhanpaul M, Morris A et al. Systemic exposure, tolerability and efficacy of pimecrolimus 1% cream in atopic dermatitis patients. Arch Dis Child 2003: 88: 969-973.
2. Wellington K, Noble S. Pimecrolimus: A review of its use in atopic dermatitis. Am J Clin Dermatol 2004: 5: 479-495.
3. Grassberger M, Steinhoff M, Schneider D et al. Pimecrolimus -an anti-inflammatory drug targeting the skin. Exp Dermatol 2004: 13: 721-730.
4. Papp K A, Werfel T, Fölster-Holst R et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants: A 2-year study. J Am Acad Dermatol 2005: 52: 240-246.
5. Van Leent E J M, Ebelin M E, Burtin P, Dorobek B, Spuls P I, Bos J D. Low systemic exposure after repeated topical application of pimecrolimus (Elidel ®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002: 204: 63-68.
6. Staab D, Pariser D, Gottlieb A B et al. Low systemic absorption and good tolerability of pimecrolimus administered as 1% cream (Elidel ®) in infants with atopic dermatitis -A multicenter, 3-week, open-label study. Pediatr Dermatol 2005: 22: 465-471.
7. Rappersberger K, Komar M, Ebelin M E et al. Pimecrolimus identifies a common genomic anti- inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002: 119: 876-888.
8. Food and Drug Administration Public Health Advisory. Elidel (pimecrolimus) Cream and Protopic (tacrolimus) Ointment. Available at http://www.fda.gov/cder/drug/advisory/elidel_protopic.htm. March 10, 2005.
9. Food and Drug Administration Pediatric Advisory Committee. Briefing Information. Available at http://www.fda.gov/ohrms/dockets/ac/05/ briefing/2005-4089b2.htm. February 15, 2005.
10. Papp K A, Breuer K, Meurer M et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005: 52: 247-253.
11. Wahn U, Bos J D, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002: 110: e2.